Faricimab- Can it Reset the Recent Safety Doomed Innovations in Retinal Pharmacotherapy?

Abstract

After the consecutive success of multiple anti-VEGF molecules in the last decade such as ranibizumab, bevacizumab and aflibercept, innovations in the retinal pharmacotherapy has gone through a rough phase in the recent past. Multiple promising molecules such as brolucizumab and aflibercept faced drug induced inflammation. Furthermore ranibizumab port delivery system was associated with procedure related vitreous hemorrhage, which though improved after modification in the surgical procedure, still is a challenge. Faricimab is another innovative molecule that has shown excellent safety and efficacy in the phase 3 trials. We hope that entry of Faricimab might reset the recent safety doomed innovations in retinal pharmacotherapy?